Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Ankylosing Spondylitis
NCT02201043Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Feb 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of thalidomide in ankylosing spondylitis (AS) (3 arms), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoint: Assessment in Ankylosing Spondylitis 20 Response at 12 weeks. Started Feb 2013; status: completed.
02
Drugs
thalidomide
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02201043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201043.